Lymphoma News

Chimeric antigen receptor T-cell therapy can be administered at community centers and on an outpatient basis with proper preparation, education and resources, according to prospective study results.

Disparities in hematopoietic stem cell transplantation utilization for blood cancers have narrowed over time but still persist, according to study results.

Multiple studies published since this summer suggest chimeric antigen receptor T-cell therapies are comparably effective in real-world settings as they have been in pivotal clinical trials.

Nivolumab plus chemotherapy significantly extended PFS for children and adults with newly diagnosed advanced Hodgkin lymphoma compared with standard of care, according to results of a randomized phase 3 trial.

Stage at diagnosis and survival among younger individuals with cancer varied considerably by race, according to a retrospective cohort study.

Systemic treatment strategies lower the risk for new Sjögren’s disease activity when there are complications with marginal zone lymphoma, according to a study published in The Lancet Rheumatology.

A meta-analysis of patients who underwent chimeric antigen receptor T-cell therapy for advanced blood cancers showed low prevalence of cardiovascular adverse events.

Older adults diagnosed with a blood cancer exhibited similar rates of cognitive decline as cancer-free controls, according to study results.

SGLT2 inhibition may prevent cancer therapy-related cardiac dysfunction and improve other outcomes in patients with diabetes undergoing cancer therapy, researchers reported.